Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group.
复制标题
四种不同治疗方案在 64 例套细胞淋巴瘤病例中的疗效：与 498 例其他非霍奇金淋巴瘤亚型的临床病理学比较。
DOI：
--
复制
发表时间：
1995
影响因子：
45.3
通讯作者：
C. Peeters
中科院分区：
文献类型：
--
作者：
I. Teodorović;S. Pittaluga;J. Kluin;J. H. Meerwaldt;A. Hagenbeek;M. Glabbeke;R. Somers;L. Bijnens;E. Noordijk;C. Peeters
目的
在认识到套细胞淋巴瘤(MCL)是一个不同的实体之前，这些患者根据工作方案被分成低级别(LG)或中/高级别(IGHG)，并接受了各种治疗。这是一个独特的机会，可以评估欧洲癌症研究和治疗组织(EORTC)进行的两项第三阶段试验的MCL患者的特征、行为、治疗反应和结果：EORTC 20855 IGHG和EORTC 20856 LG。
患者和方法
经过组织学回顾，诊断的MCL患者(29例IGHG和35例LG)与各自试验中的其他患者进行了比较。IGHG组患者接受环磷酰胺、阿霉素、替尼平(VM26)、强的松、长春新碱、博莱霉素(CHVmP-VB)或改良的阿霉素、环磷酰胺、依托泊苷(VP16)、甲硝胺、长春新碱、丙卡巴肼、强的松(ProMACE-MOPP)治疗。在LG组，在接受环磷酰胺、长春新碱和强的松(CVP)诱导后，患者被随机分为干扰素α-2a(干扰素)维持治疗和不进一步治疗两组。
结果
MCL患者与IGHG亚型患者相比，总体生存率和缓解率相似，但缓解期和无进展生存期较短。与LG患者相比，他们的有效率、有效时间和无进展生存期没有差异，而他们的总体生存期缩短了近两倍。经CHVmP-VB治疗的MCL患者存活时间最长。没有任何治疗显示在无进展存活率方面有任何显著的改善。
结论
这些数据证实了MCL是一种临床病理实体。在生存方面，它表现为IGHG亚型，而在无进展生存方面，它表现为LG淋巴瘤。目前尚不清楚哪种一线治疗为MCL患者提供了获得完全缓解(CR)和长期生存的最好机会。
PURPOSE
Before recognizing mantle-cell lymphoma (MCL) as a distinct entity, these patients were grouped into low-grade (LG) or intermediate-/high-grade categories (IGHG) according to the Working Formulation and received various therapies. This was a unique opportunity to evaluate characteristics, behavior, response to treatment, and outcome of patients with MCL from two phase III trials conducted by the European Organization for the Research and Treatment of Cancer (EORTC): EORTC 20855 IGHG and EORTC 20856 LG.
PATIENTS AND METHODS
After histologic review, 64 diagnosed MCL patients (29 IGHG and 35 LG) were compared with other patients in their respective trials. In the IGHG group, patients received cyclophosphamide, doxorubicin, teniposide (VM26), prednisone, vincristine, and bleomycin (CHVmP-VB) or modified doxorubicin, cyclophosphamide, etoposide (VP 16), mechlorethamine, vincristine, procarbazine, and prednisone (ProMACE-MOPP). In the LG group, after receiving cyclophosphamide, vincristine, and prednisone (CVP) induction, patients were randomized between maintenance treatment with interferon alfa-2a (IFN) or no further treatment.
RESULTS
MCL patients compared with IGHG subtypes showed a similar overall survival and response rate, but shorter duration of response and progression-free survival. Comparing with LG patients, their response rate, duration of response, and progression-free survival showed no difference, while their overall survival was nearly twice shorter. MCL patients treated with CHVmP-VB had the longest survival. No treatment showed any significant improvement in terms of progression-free survival.
CONCLUSION
These data confirm that MCL represents a clinicopathologic entity. In terms of survival, it behaves like IGHG subtypes, while in terms of progression-free survival, it behaves like LG lymphoma. It is still not clear which first-line treatment offers patients with MCL the best chance to obtain both a complete response (CR) and a long-term survival.
DOI：
10.1073/pnas.88.21.9638
发表时间：
1991-11-01
影响因子：
11.1
作者：
ROSENBERG, CL;WONG, E;ARNOLD, A
通讯作者：
ARNOLD, A
影响因子：
20.3
作者：
FISHER, RI;DAHLBERG, S;GROGAN, TM
通讯作者：
GROGAN, TM